EUVIMEDEUVIMED entdecken
Crossref

Clinical Pharmacogenomic MT‐RNR1 Screening for Aminoglycoside‐Induced Ototoxicity and the Post‐Test Counseling Conundrum

Robert Rigobello iD, Jay Shaw iD, Daniel Ilg iD, Rebekah Zimmerman iD, Lisa Edelmann iD, Ruth Kornreich, Stuart A Scott iD, Neal Cody

Clinical Pharmacology & Therapeutics · 2023

DOI: 10.1002/cpt.2910 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2023. Verfasst von Robert Rigobello und 7 weiteren Autor:innen. Beteiligte Einrichtung: GeneDx, Gaithersburg, Maryland, USA. Hauptthemen laut MEDLINE: Aminoglycosides, Genes, rRNA, Ototoxicity. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 12 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aminoglycoside antibiotic exposure can result in ototoxicity and irreversible hearing loss among individuals that harbor the m.1555A>G variant in the mitochondrial 12S rRNA gene, MT‐RNR1 . Importantly, pre‐emptive m.1555A>G screening has been shown to reduce the prevalence of pediatric aminoglycoside‐induced ototoxicity; however, professional guidelines to support and guide post‐test pharmacogenomic counseling in this context are not currently available. This Perspective highlights key issues with delivering MT‐RNR1 results, including longitudinal familial care considerations and communicating m.1555A>G heteroplasmy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AminoglycosidesGenes, rRNAOtotoxicityChildHumansAnti-Bacterial AgentsDNA, MitochondrialMutationPharmacogenetics

Substanzen

AminoglycosidesAnti-Bacterial AgentsDNA, Mitochondrial

Autor:innen und Institutionen

  • GeneDx, Gaithersburg, Maryland, USA.
  • Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Department of Pathology, Stanford University, Stanford, California, USA.
  • Clinical Genomics Laboratory, Stanford Medicine, Palo Alta, California, USA.

ORCID-Profile: Robert Rigobello, Jay Shaw, Daniel Ilg, Rebekah Zimmerman, Lisa Edelmann, Stuart A Scott

Zitieren

APA

Rigobello, R., Shaw, J., Ilg, D., Zimmerman, R., Edelmann, L., Kornreich, R., Scott, S. A., & Cody, N. (2023). Clinical Pharmacogenomic MT‐RNR1 Screening for Aminoglycoside‐Induced Ototoxicity and the Post‐Test Counseling Conundrum. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.2910

Vancouver

Rigobello R, Shaw J, Ilg D, Zimmerman R, Edelmann L, Kornreich R, et al. Clinical Pharmacogenomic MT‐RNR1 Screening for Aminoglycoside‐Induced Ototoxicity and the Post‐Test Counseling Conundrum. Clinical Pharmacology & Therapeutics. 2023. doi:10.1002/cpt.2910

BibTeX
@article{Rigobello2023,
  author = {Rigobello, Robert and Shaw, Jay and Ilg, Daniel and Zimmerman, Rebekah and Edelmann, Lisa and Kornreich, Ruth and Scott, Stuart A and Cody, Neal},
  title = {Clinical Pharmacogenomic MT‐RNR1 Screening for Aminoglycoside‐Induced Ototoxicity and the Post‐Test Counseling Conundrum},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2023},
  doi = {10.1002/cpt.2910}
}
Kostenlos starten →